Tracking a new drug Combo's Real-Life impact on advanced breast cancer
NCT ID NCT05253911
Summary
This study observed how well a drug combination (tucatinib with trastuzumab and capecitabine) worked for 49 adults in Germany and Austria with advanced HER2-positive breast cancer that had worsened after at least two prior treatments. The main goal was to see how the treatment affected patients' quality of life in a real-world setting, including older patients and those with other health issues. Researchers also tracked how long the treatment worked and monitored for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medizinische Universität Wien, Innere Medizin I, Hämatologie und Onkologie
Vienna, 1090, Austria
-
Universitätsklinikum Essen, Innere Klinik (Tumorforschung)
Essen, North Rhine-Westphalia, D-45112, Germany
Conditions
Explore the condition pages connected to this study.